Canopy Growth GAAP EPS of -C$0.10 misses by C$0.07, revenue of C$81.3M misses by C$0.75M (CGC:NASDAQ)

Canopy Growth reported Q2 GAAP EPS of -C$0.10, missing estimates by C$0.07, with revenue of C$81.3M, up 21.9% Y/Y but missing by C$0.75M. Medical and adult-use cannabis revenue in Canada grew 18% and 17%, respectively.

Original reporting
Published Nov 6, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CGC
Bearish
high confidence
Mentioned
$CGC
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CGCBearishMed
01

Why it matters

The earnings miss is likely to depress the stock in the near term, with sector peers possibly feeling spillover effects.

02

Market read

Earnings miss for a mid‑cap cannabis stock; short‑term downside risk for CGC and potential sector drag.

03

What to watch

Potential cost‑saving measures or upcoming product launches not disclosed in the brief could mitigate downside.

Relevance 7/10Novelty 7/10Timing: after-hours reaction

Background

Canopy Growth reported its Q2 2026 results, showing a GAAP EPS miss and slight revenue shortfall.

Company-level read

Ticker impact

$CGCBearishHigh confidence
Context

Q2 GAAP EPS of -C$0.10 missed expectations by C$0.07 and revenue of C$81.3M missed by C$0.75M, marking a fresh earnings miss.

Expected impact

downward pressure as market prices in the earnings shortfall

Evidence & confidence

Both EPS and revenue fell short of consensus, a typical catalyst for a sell‑off in cannabis stocks.

Market effects

May weigh on broader Canadian cannabis sector as peers are compared to CGC's miss.

Limited to North American cannabis equities.

Low; impact confined to sector-specific investors.

Counterpoint

If the miss is already priced in, the stock could stabilize or rebound on short covering.

Key entities

  • Canopy Growth Corporation

    Canadian cannabis producer listed on NASDAQ (CGC).

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.